In both the United States and other parts of the world, kidney stones are becoming an increasingly regular occurrence. There is a correlation between type 2 diabetes and an increased risk of kidney stones; however, there are a variety of treatment options available for this condition that have the ability to minimize the risk of kidney stones formation.
The use of sodium-glucose contratransporter 2 (SGLT2) inhibitors was found to be connected with a reduced risk of developing kidney stones, according to the findings of researchers at Mass General Brigham. Their results were later reported in the journal JAMA Internal Medicine.
The investigation was carried out by researchers from Massachusetts General Hospital and Brigham and Women’s Hospital working together to undertake the investigation. The research incorporated information obtained from three national databases pertaining to individuals diagnosed with type 2 diabetes who were seen in the course of their regular clinical practice. In their study, the researchers looked at information from 716,406 people who had type 2 diabetes and had started taking either an SGLT2 inhibitor or one of two additional types of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
In comparison to patients who were using GLP1 agonists, those who started taking SGLT2 inhibitors had a thirty percent lower risk of developing kidney stones, and those who started taking DPP4 inhibitors had a twenty-five percent lower risk altogether. The findings were constant regardless of factors such as gender, race or ethnicity, a previous history of chronic renal illness, or obesity.
“Our findings could help inform clinical decision making for patients with diabetes who are at risk of developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of Brigham and Women’s Hospital’s Divisions of Pharmacoepidemiology and Pharmacoeconomics and Renal (Kidney) Medicine.
For more information: Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2023.7660
more recommended stories
Maternal Diet Fails to Reduce Infant Egg and Peanut AllergyKey Points A large Australian randomized.
Psychedelic-Assisted Psychotherapy: Music in TreatmentKey Takeaways Psychedelic-assisted psychotherapy combines psychedelic.
Cardiovascular Frailty Links Heart Health and AgingKey Points Cardiovascular frailty may connect.
Laser Blended Vision: Simple Test Predicts SuccessKey Points A simple phoropter-based test.
Pink Noise Boosts Brain Waste Clearance During SleepKey Points Pink noise delivered during.
Psilocybin Microdosing Research Raises Key QuestionsKey points: Psilocybin microdosing research shows.
Maternal Illness Linked to Epigenetic Fetal Brain ChangesMaternal illness during pregnancy may influence.
SGLT2 Inhibitors Boost Cardiac Energy Through PANK1Key Points SGLT2 inhibitors directly activate.
Daraxonrasib Approved for Metastatic Pancreatic CancerKey Points FDA approved daraxonrasib (RASONQUE).
Nicotine E-Cigarettes Help More Smokers Quit Than NRTKey Points Nicotine e-cigarettes helped more.
Leave a Comment